Heterocyclic derivatives as camkk2 inhibitors
AssigneeBristol-Myers Squibb Company
InventorsYoung Chen, Michael Wallace, Zhe Nie, Laura D'Agostino
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to compositions and methods for treating cancer, e.g. by using the compounds of formula (I). Provided herein are substituted bicyclic heteroaryl derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of Calcium/calmodulin-dependent protein kinase kinase 2. Furthermore, the subject compounds and compositions are useful for the treatment of cancer.
Claims15
A compound of Formula (I), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is alkyl, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or amine;
- and
- R2 is optionally substituted aryl.
A compound of Formula (IIa), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is alkoxy, cycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, or amine;
- R2 is optionally substituted aryl;
- and
- X is hydrogen or halogen.
The compound of claim 15, wherein R2 is aryl optionally substituted by at least one substituent chosen from carbonyl, alkoxy, or cycloalkyl.
A compound of Formula (IIb), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is optionally substituted aryl;
- R2 is optionally substituted aryl;
- and
- X is hydrogen or halogen.
A compound of Formula (IIc), or a pharmaceutically acceptable salt thereof,
- wherein,
- R1 is optionally substituted aryl;
- R2 is optionally substituted aryl;
- and
- X is hydrogen or halogen.
A compound of Formula (III), or a pharmaceutically acceptable salt thereof,
- wherein,
- W is carbon or nitrogen;
- R1 is alkoxy, cyclylalkoxy, heterocyclyl, or heteroaryl;
- R2 is optionally substituted aryl;
- and
- X1, X2, and X3 is independently hydrogen or halogen.
Dependencies are inferred from the claim text.